Table 1. The clinicopathological variables and their association with low- and high 16-miRNA signature.

Study Cohort n= 111	Total (nL)	16-miRNA signature		p-valuea
		Low (%) n= 48	High (%) n= 63
Age				NS
≤72.5	49	47.9	41.3
>72.5	62	52.1	58.7
Gender				NS
Female	51	50	42.9
Male	60	50	57.1
TNM stageb				0.004
II	66	75	47.6
III	45	25	52.4
MMR status				NS
Deficient	24	22.7	26.4
Proficient	73	77.3	73.6
ND	14
Tumor differentiation				NS
Well/Moderate	88	81.3	77.8
Poor	21	18.8	19
ND	2	0	3.2
Histology type				NS
Adenocarcinoma	101	89.6	92.1
Variantc	10	10.4	7.9
Adjuvant therapy				NS
Yes	25	20.8	23.8
No	86	79.2	76.2
Validation Cohort n= 209		Low (%) n= 90	High (%) n= 119
Age				NS
≤66.5	92	37.8	48.7
>66.5	117	62.2	51.3
Gender				NS
Female	98	41.1	51.3
Male	111	58.9	48.7
TNM stage				NS
II	122	61.1	56.3
III	87	38.9	43.7
MSI status				NS
MSS	135	58.9	68.9
MSI Low	30	14.4	14.3
MSI High	44	26.7	16.8

^aP-values from Chi-square, ^bTNM tumour, node metastasis classification of malignant tumours, ^cVariant includes signet ring and mucinous carcinoma, NS= not significant (p > 0.05), ND= not determined.